Corporate | 19 October 2011 13:37
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Miscellaneous
19.10.2011 / 13:37
---------------------------------------------------------------------
Berlin, October 19, 2011. This year's travel grants from Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700) have been awarded to
five nuclear medicine scientists from Australia, Germany, the Netherlands
and Switzerland. The prize-winners were selected by a jury from the
European Association of Nuclear Medicine (EANM) from a total of 482
entries. Work in the fields of oncologic, cardiovascular and pulmonary
diagnostic as well as in the field of oncologic therapy received
recognition. The travel grants, which amount to 1,000 EUR each, were
presented today at the annual congress of the EANM in Birmingham to:
T. Heusner, Germany: Diagnostic accuracy of virtual 3D FDG-PET/CT
bronchoscopy for the detection of lymph node metastases in non small cell
lung cancer patients
M. Hofmann, Australia: Gallium-68 PET/CT Ventilation Perfusion Imaging for
Acute Pulmonary Embolism
C. Kobe, Germany: Assessment of residual bulky tumor using FDG-PET in
patients with advanced stages after completion of chemotherapy. Final
report of the GHSG
HD15 trial
J. Schaap, Netherlands: Coronary calcium scoring does not add to myocardial
perfusion SPECT in the exclusion of coronary artery disease in high risk
patients
M. Walter, Switzerland: [90Yttrium-DOTA]-TOC vs. [90Yttrium-DOTA]-TOC plus
[177Lutetium-DOTA]-TOC in Metastasized Neuroendocrine Cancers
'The nuclear imaging highly contributes to the early diagnosis of cancer
and neurological diseases such as Alzheimer's. A huge number of biological
markers helping to make the process of a disease visible are at present in
the state of development. The future belongs to the imaging biomarkers',
explained Dr. Andreas Eckert, CEO of Eckert & Ziegler.
In presenting the 'EANM Eckert & Ziegler Abstract Award' Eckert & Ziegler
wishes to encourage young researchers to present their results to a wider
audience.
Eckert & Ziegler AG is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine. The Berlin
based company has 570 employees and is listed at the Frankfurt stock
exchange.
You can find further information about the Eckert & Ziegler travel grant at
http://www.ezag.com/home/about-us/social-engagement/abstract-award.html
Your contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations & PR
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 941084-138, Fax-112
E-mail: karolin.riehle@ezag.de, www.ezag.com
End of Corporate News
---------------------------------------------------------------------
19.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
142767 19.10.2011